Cervical cancer

@article{Waggoner2003CervicalC,
  title={Cervical cancer},
  author={Steven E. Waggoner},
  journal={The Lancet},
  year={2003},
  volume={361},
  pages={2217-2225}
}
Cervical cancer is a serious health problem, with nearly 500000 women developing the disease each year worldwide. Most cases occur in less developed countries where no effective screening systems are available. Risk factors include exposure to human papillomavirus, smoking, and immune-system dysfunction. Most women with early-stage tumours can be cured, although long-term morbidity from treatment is common. Results of randomised clinical trials have shown that for women with locally advanced… Expand
Cervical cancer
TLDR
For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Expand
SEOM guidelines for cervical cancer
TLDR
In the setting of recurrent or metastatic CC the treatment is largely palliative, so it is important to develop new therapeutic strategies. Expand
Cervical cancer prevention: making programs more appropriate and pragmatic.
TLDR
Three articles published in this issue of JAMA provide new and practical insights into how cervical cancer prevention efforts could be improved among women at highest risk for disease. Expand
Advances in the management of cervical cancer
TLDR
An improved understanding of the viral aetiology of cervical cancer has led to the development of therapeutic vaccination, with limited success, and increasing recognition of the psychosexual needs of women who have survived cervical cancer. Expand
Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer
TLDR
Cervical cancer, its cause, symptoms, pathophysiology and treatments are discussed and early screening and detection can help in reducing the overall burden of cervical cancer in the near future. Expand
Targeted Agents in Cervical Cancer: Beyond Bevacizumab
TLDR
Bvacizumab, an antiangiogenic agent that targets vascular endothelial growth factor 2 (VEGF-2), added to standard chemotherapy in cervical cancer showed significant improvement on survival; therefore, the combination of carboplatin, paclitaxel, and bevacIZumab is currently the standard frontline treatment in cervicalcancer. Expand
Human Papillomavirus and Management of Cervical Cancer: Does Genotype Matter
TLDR
HPV infection has been established as an etiologic agent for cervical carcinoma and a high-risk group defined by preoperative variables including HPV-18 positivity is associated with a high probability of postoperative radiotherapy or concurrent chemoradiation (RT/CCRT). Expand
Role of Chemotherapy in Recurrent Cervical Cancer
Approximately 30% of cervical cancer patients will ultimately fail after definitive treatment. The reported 5-year survival rates of patients with treatment failure are between 3.2% and 13%.Expand
Vaginal morphological changes in cervical cancer survivors
TLDR
The vaginal wall is markedly changed in irradiated cervical cancer survivors and the connective tissue is remodeled with elastosis and radiotherapy-induced fibrosis, and the vaginal epithelium volume is reduced, compared to controls with similar levels of estradiol. Expand
Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy.
  • Hakyoung Kim, W. Cho, Yeon Joo Kim, Young Seok Kim, Won Park
  • Medicine
  • Gynecologic oncology
  • 2020
TLDR
Patients with early-stage cervical cancer having multiple high-risk factors, adenocarcinoma histologic type, and pelvic lymph node metastasis accompanied by a higher lymph node ratio after surgery are more likely to have occult distant metastasis. Expand
...
1
2
3
4
5
...